{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T09:18:11Z","timestamp":1761297491672,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Background: Primary central nervous lymphoma (PCNSL) is a rare, aggressive, non-Hodgkin\u2019s lymphoma. Outcomes are poor with standard induction of high-dose methotrexate (HD-MTX)-based regimens and consolidation. We present retrospective data from the Georgia Cancer Center. Methods: A single retrospective chart review was conducted on all PCNSL patients from 2013 to 2023 to assess for various factors influencing care. Results: Of a total of 38 PCNSL patients, 6 died and 2 were lost to follow-up prior to therapy initiation, leading to a total of 30 patients for analysis. The median age was 62.3 (21\u201382 years). One patient had HIV\/AIDS. Two patients were on immunosuppression for either kidney transplant or multiple sclerosis (MS). The HIV and MS cases were Epstein-Barr Virus (EBV)-positive. Completion of \u2265six cycles of induction was predictive of response. Conclusions: PCNSL remains an area of high unmet need. Recent studies have shown that HD-MTX-based therapy and autologous stem cell transplantation afterwards leads to improved outcomes regardless of age; however, non-relapse mortality is important to consider. Our data from a primarily elderly and sub-rural cohort reiterate the efficacy of combination chemoimmunotherapy and impact of induction cycle number on response, regardless of age. A multidisciplinary approach and targeted agent maintenance should be considered to improve outcomes in the elderly.<\/jats:p>","DOI":"10.3390\/hematolrep17060055","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:53:25Z","timestamp":1761296005000},"page":"55","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes for Primary Central Nervous System Lymphoma from a Single Institution"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6454-6243","authenticated-orcid":false,"given":"Sruthi","family":"Dontu","sequence":"first","affiliation":[{"name":"Medical College of Georgia (MCG), Augusta University, Augusta, GA 30912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Boccucci","sequence":"additional","affiliation":[{"name":"Department of Medicine, Wellstar MCG Health Medical Center, Augusta University, Augusta, GA 30912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Chahin","sequence":"additional","affiliation":[{"name":"Summit Cancer Care, Savannah, GA 31405, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7205-3975","authenticated-orcid":false,"given":"Amany","family":"Keruakous","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Georgia Cancer Center, Wellstar MCG Health Medical Center, Augusta University, Augusta, GA 30912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Jillella","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Georgia Cancer Center, Wellstar MCG Health Medical Center, Augusta University, Augusta, GA 30912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Georgia Cancer Center, Wellstar MCG Health Medical Center, Augusta University, Augusta, GA 30912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5290-9289","authenticated-orcid":false,"given":"Vamsi","family":"Kota","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Georgia Cancer Center, Wellstar MCG Health Medical Center, Augusta University, Augusta, GA 30912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Locke","family":"Bryan","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Georgia Cancer Center, Wellstar MCG Health Medical Center, Augusta University, Augusta, GA 30912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4962-3965","authenticated-orcid":false,"given":"Ayushi","family":"Chauhan","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Texas Medical Center, The University of Texas, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"ref_1","unstructured":"Green, K., Munakomi, S., and Hogg, J.P. (2025, May 05). Central Nervous System Lymphoma. PubMed. Published 2021, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK545145\/."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Morales-Martinez, A., Lozano-Sanchez, F., Duran-Pe\u00f1a, A., Hoang-Xuan, K., and Houillier, C. (2021). Primary Central Nervous System Lymphoma in Elderly Patients: Management and Perspectives. Cancers, 13.","DOI":"10.3390\/cancers13143479"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjh.14073","article-title":"Trends in primary central nervous system lymphoma incidence and survival in the U.S.","volume":"174","author":"Shiels","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/bjc.2011.357","article-title":"Age, gender, and racial differences in incidence and survival in primary CNS lymphoma","volume":"105","author":"Villano","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e1027","DOI":"10.1212\/WNL.0000000000008900","article-title":"Management and outcome of primary CNS lymphoma in the modern era","volume":"94","author":"Houillier","year":"2020","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.14744\/SEMB.2025.24022","article-title":"Primary Central Nervous System Lymphomas: A Single-Center Experience","volume":"59","author":"Ozkan","year":"2025","journal-title":"SiSli Etfal Hastan. Tip Bul.\/Med. Bull. Sisli Hosp."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000495284","article-title":"Primary CNS Lymphoma in the Elderly: The Challenge","volume":"141","author":"Siegal","year":"2019","journal-title":"Acta Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.21037\/aol-20-30","article-title":"Treatment of elderly patients with primary CNS lymphoma","volume":"5","author":"Isbell","year":"2021","journal-title":"Ann. Lymphoma"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.16592","article-title":"Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: Methotrexate dose intensity correlates with response and survival","volume":"190","author":"Poynton","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bjh.16451","article-title":"Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system\u2014An international study of feasibility and efficacy in routine clinical practice","volume":"189","author":"Schorb","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00701-022-05170-5","article-title":"Diagnosis, treatment, and outcome of primary CNS lymphoma\u2014A single-center experience","volume":"164","author":"Wismann","year":"2022","journal-title":"Acta Neurochir."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11060-022-04014-7","article-title":"Primary CNS lymphoma of the corpus callosum: Presentation and neurocognitive outcomes","volume":"158","author":"Nilles","year":"2022","journal-title":"J. Neuro-Oncol."},{"key":"ref_13","unstructured":"(2025, October 15). CTCAE and AE Reporting, Available online: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events#ctcae."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1182\/blood-2023-191136","article-title":"Academic Outreach and Collaboration with Community Oncology Practices to Enhance Referrals and Reduce Disparities in Hematological Malignancies","volume":"142","author":"Kota","year":"2023","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"LBA-3","DOI":"10.1182\/blood-2022-171733","article-title":"Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma\u2014Results of an International Randomized Phase III Trial (MATRix\/IELSG43)","volume":"140","author":"Illerhaus","year":"2022","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(23)00371-X","article-title":"High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): A single-arm, phase 2 trial","volume":"11","author":"Schorb","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_17","first-page":"113","article-title":"Imaging Features of Immunodeficiency-Associated Primary CNS Lymphoma: A Review","volume":"76","author":"Torres","year":"2024","journal-title":"Can. Assoc. Radiol. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1215\/15228517-2008-103","article-title":"Racial differences in primary central nervous system lymphoma incidence and survival rates","volume":"11","author":"Pulido","year":"2009","journal-title":"Neuro-Oncology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/blood-2023-184982","article-title":"Racial and Ethnic Disparities for Primary CNS Lymphoma: A National Cancer Database Analysis with Emphasis on Hispanics","volume":"142","author":"Rosas","year":"2023","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e14553","DOI":"10.1200\/JCO.2020.38.15_suppl.e14553","article-title":"Never too young: Retrospective study on age and racial disparity in the outcome of primary CNS Lymphoma in south Texas","volume":"38","author":"Ananth","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2020002064","article-title":"High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: A pilot study","volume":"4","author":"Schorb","year":"2020","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1034668","DOI":"10.3389\/fonc.2022.1034668","article-title":"Bruton\u2019s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review","volume":"12","author":"Shen","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_25","unstructured":"(2025, October 16). Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04947319."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Li, Y., Zhuang, Z., Wang, W., Wei, C., Zhao, D., Zhou, D., and Zhang, W. (2021). Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.760405"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2022-164677","article-title":"Zanubrutinib, Lenalidomide, Rituximab, Temozolomide and Methotrexate (RLZT\u00b1MTX) As First-Line Treatment for Newly Diagnosed PCNSL: A Prospective, Open-Lable, Multicenter Clinical Trial","volume":"140","author":"Song","year":"2022","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2023.11.010","article-title":"Primary central nervous system lymphomas: EHA\u2013ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Ferreri","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"12070","DOI":"10.1182\/blood-2022-158730","article-title":"Investigation of High Dose Cytarabine Plus Zanubrutinib in Relapsed\/Refractory Primary Central Nervous System Lymphoma","volume":"140","author":"Lin","year":"2022","journal-title":"Blood"},{"key":"ref_30","unstructured":"(2025, October 16). Zanubrutinib Monotherapy in Relapsed\/Refractory Central Nervous System Lymphoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05117814."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1463505","DOI":"10.3389\/fonc.2024.1463505","article-title":"BTK inhibition in primary central nervous system lymphoma: Mechanisms, clinical efficacy, and future perspectives","volume":"14","author":"Xing","year":"2024","journal-title":"Front. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e791","DOI":"10.1200\/JOP.19.00566","article-title":"Decreasing Cost and Decreasing Length of Stay After Implementation of Updated High-Dose Methotrexate Discharge Criteria","volume":"16","author":"Binder","year":"2020","journal-title":"JCO Oncol. Pract."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/6\/55\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T09:14:08Z","timestamp":1761297248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/6\/55"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["hematolrep17060055"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep17060055","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]}}}